Böhm M, Schunter JA, Fritz K, et al. S1 guideline: diagnosis and therapy of vitiligo. J Dtsch Dermatol Ges. 2022;20(3):365–78.

PubMed  Google Scholar 

van Geel N, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37(11):2173–84.

Article  PubMed  Google Scholar 

AL-smadi K, Imran M, Leite-Silva VR, et al. Vitiligo: a review of aetiology, pathogenesis, treatment, and psychosocial impact. Cosmetics. 2023;10(3):84.

Article  CAS  Google Scholar 

Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124–8.

Article  PubMed  PubMed Central  Google Scholar 

Seneschal J, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force part 2: specific treatment recommendations. J Eur Dermatol Venerol. 2023;37(11):2185–95.

Article  Google Scholar 

Martins C, Migayron L, Drullion C, et al. Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling. J Investig Dermatol. 2022;142(4):1194-205.e7.

Article  CAS  PubMed  Google Scholar 

Incyte Biosciences Distribution B.V. Opzelura 15 mg/g cream: EU summary of product characteristics. 2023. https://www.ema.europa.eu. Accessed 20 Mar 2024.

Incyte Biosciences UK Ltd. Opzelura 15mg/g cream: UK summary of product characteristics. 2023. https://products.mhra.gov.uk. Accessed 20 Mar 2024.

Incyte Corporation. OPZELURA™ (ruxolitinib) cream, for topical use: US prescribing information. 2022. https://dailymed.nlm.nih.gov. Accessed 20 Mar 2024.

Hoy SM. Ruxolitinib cream 1.5%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2023;24(1):143–51.

Article  PubMed  Google Scholar 

Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Investig Dermatol. 2011;131(9):1838–44.

Article  CAS  PubMed  Google Scholar 

Persaud I, Diamond S, Pan R, et al. Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs. Int J Pharm. 2020;590(119889):1–6.

Google Scholar 

Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054-60.e1.

Article  CAS  PubMed  Google Scholar 

Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110–20.

Article  CAS  PubMed  Google Scholar 

Harris JE, Pandya AG, Lebwohl M, et al. Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: 156-week data from a phase II study [abstract no. P96 plus poster]. Br J Dermatol. 2022;187(Suppl. 1):80–1.

Google Scholar 

Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445–55.

Article  CAS  PubMed  Google Scholar 

Rosmarin D, Ezzedine K, Desai S. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: pooled subgroup analysis from two randomized phase 3 studies [abstract no. 35187 plus poster]. J Am Acad Dermatol. 2022;87(3):AB50.

Article  Google Scholar 

Rosmarin D, Ezzedine K, Md P, et al. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo: week 24 pooled analysis of the TRuE-V phase 3 studies [abstract no. 34789 plus poster]. J Am Acad Dermatol. 2022;87(3):AB51.

Article  Google Scholar 

Ezzedine K, van Geel N, Butler K, et al. Subgroup analysis of quality of life and treatment satisfaction by disease duration and use of prior treatment: pooled results from two randomized phase 3 studies of ruxolitinib cream for the treatment of vitiligo [abstract no. CO108 plus poster]. Value Health. 2022;25(7 Suppl.):S324.

Article  Google Scholar 

Pandya AG, van Geel N, Butler K, et al. Subgroup analysis of quality of life and treatment satisfaction by baseline patient characteristics: pooled results from two randomized phase 3 studies of ruxolitinib cream for the treatment of vitiligo [abstract no. CO96 plus poster]. Value Health. 2022;25(7 Suppl.):S321–2.

Article  Google Scholar 

Harris JE, Rosmarin D, Seneschal J, et al. Facial vitiligo area scoring index response maintenance or shift during 52 weeks of ruxolitinib cream treatment for vitiligo: pooled analysis of the TRuE-V phase 3 studies [abstract no. 43912 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.

Rosmarin D, Harris JE, Wolkerstorfer A, et al. Total vitiligo area scoring index response maintenance or shift during 52 weeks of ruxolitinib cream treatment for vitiligo: pooled analysis of the TRuE-V phase 3 studies [abstract no. 43938 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.

Ezzedine K, Passeron T, Rosmarin D, et al. Vitiligo noticeability scale score maintenance or shift during 52 weeks of ruxolitinib cream treatment for vitiligo: pooled analysis of the TRuE-V phase 3 studies [abstract no. 43959 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.

Seneschal J, Wolkerstorfer A, Desai SR, et al. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: week 52 pooled subgroup analysis from two randomized phase 3 studies [abstract no. 555 plus poster P1383]. In: 31st European Academy of Dermatology and Venereology (EADV) Congress. 2022.

Seneschal J, Grimes P, Desai SR, et al. Efficacy and safety of ruxolitinib cream in adolescent patients with vitiligo: pooled analysis of the 52-week TRuE-V phase 3 studies. In: Society for Pediatric Dermatology 47th Annual Meeting. 2022.

Seneschal J, Wolkerstorfer A, Ezzedine K, et al. Efficacy and safety of ruxolitinib cream through week 104 in patients with vitiligo: subgroup analysis of the TRuE-V long-term extension phase 3 study [abstract no. 927 plus poster P2229]. In: 32nd European Academy of Dermatology and Venereology (EADV) Congress. 2023.

Rosmarin D, Sebastian M, Amster M, et al. Facial and total vitiligo area scoring index response shift during 104 weeks of ruxolitinib cream treatment for vitiligo: results from the open-label arm of the TRuEV long-term extension phase 3 study [abstract plus presentation]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.

Pandya AG, Ezzedine K, Rosmarin D, et al. Treatment-emergent adverse events of interest for janus kinase inhibitors: pooled analysis of the 52-week TRuE-V phase 3 studies of ruxolitinib cream treatment for vitiligo [abstract no. 43978 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.

Hu W, Thornton M, Livingston RA. Real-world use of ruxolitinib cream: safety analysis at 1 year. Am J Clin Dermatol. 2024;25(2):327–32.

Article  PubMed  PubMed Central  Google Scholar 

Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2021;186(1):18–29.

Article  PubMed  Google Scholar 

Kitchen H, Wyrwich KW, Carmichael C, et al. Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the Vitiligo Area Scoring Index (VASI). Dermatol Ther (Heidelb). 2022;12(7):1623–37.

Article  PubMed  PubMed Central  Google Scholar 

Ehsan M, Rehman AU, Ayyan M, et al. Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: a systematic review and meta-analysis of randomized controlled trials. J Cosmet Dermatol. 2023;31(1):350–3.

Article  Google Scholar